REPLIGEN CORP Proceeds from Sale and Maturity of Held-to-maturity Securities
REPLIGEN CORP (RGEN) reported Proceeds from Sale and Maturity of Held-to-maturity Securities of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-18.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities · last filed 2024-11-18
- REPLIGEN CORP proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2024-09-30 was $0.00.
- REPLIGEN CORP proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2023-09-30 was $0.00.
- REPLIGEN CORP proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2022-09-30 was $0.00.
| Period end | Proceeds from Sale and Maturity of Held-to-maturity Securities 3 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 6 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-18 | $0.00 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $0.00 10-Q/A · filed 2024-11-18 | ||
| 2023-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $102.32M 10-Q/A · filed 2024-11-18 | |
| 2023-06-30 | $102.32M 10-Q/A · filed 2024-11-18 | ||
| 2022-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | |
| 2022-06-30 | $0.00 10-Q/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |